文献速递系统性红斑狼疮

系统性红斑狼疮过早死亡率趋势未改善:一项基于一般人群的研究(1999-2014)

Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014).
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

该研究基于英国一般人群医疗记录数据库,纳入1999-2006年早期队列1470例和2007-2014年晚期队列1666例新发SLE病例及匹配对照,比较死亡率。结果显示两队列中SLE患者超额死亡率相似,死亡风险比分别为2.15和2.12,交互作用P=0.95,提示近年SLE超额死亡未见改善。

要点

  • 早期队列SLE患者死亡率为15.9/1000人年,匹配对照为7.9/1000人年。
  • 晚期队列SLE患者死亡率为13.8/1000人年,匹配对照为7.0/1000人年。
  • 两队列死亡风险比分别为2.15和2.12,交互作用P=0.95,超额死亡无改善。

核心结论

  • 这项基于一般人群的队列研究提示,近年来SLE患者的超额死亡未见改善,仍为对照组的2倍以上,与同期RA不同。
  • 作者认为这凸显了开发新治疗药物和改善SLE及其合并症管理策略的迫切未满足需求。

研究设计与样本

  • 基于英国一般人群代表性医疗记录数据库的人群队列研究。
  • 识别1999-2014年间新发SLE病例及匹配的非SLE对照。
  • 按SLE诊断年份分为早期队列(1999-2006)和晚期队列(2007-2014)。
  • 比较死亡率及风险比,并校正潜在混杂因素。

主要发现

  • 早期队列纳入1470例新发SLE病例,晚期队列纳入1666例。
  • 早期队列SLE患者死亡率为15.9/1000人年 vs 匹配对照7.9/1000人年。
  • 晚期队列SLE患者死亡率为13.8/1000人年 vs 匹配对照7.0/1000人年。
  • 早期和晚期队列死亡风险比分别为2.15(95%CI 1.63, 2.83)和2.12(95%CI 1.61, 2.80),交互作用P=0.95。
  • 早期和晚期队列绝对死亡率差异分别为8.0(95%CI 4.3, 11.8)和6.8(95%CI 3.5, 10.0)死亡/1000人年,交互作用P=0.61。

关键数值与推荐

  • 早期队列SLE患者 vs 匹配对照:死亡率15.9 vs 7.9死亡/1000人年,风险比2.15(95%CI 1.63, 2.83)。
  • 晚期队列SLE患者 vs 匹配对照:死亡率13.8 vs 7.0死亡/1000人年,风险比2.12(95%CI 1.61, 2.80)。
  • 两队列风险比交互作用P=0.95,绝对死亡率差异交互作用P=0.61。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with SLE have increased morbidity and premature mortality. Whether this mortality gap has improved in recent years, as in RA, is unknown. METHODS: We conducted a population-based cohort study using a medical records database representative of the general population of the UK. We identified incident SLE cases and matched non-SLE controls between 1999 and 2014, divided into two subgroups based on year of SLE diagnosis, forming the early cohort (1999-2006) and late cohort (2007-14). We compared the mortality rates and hazard ratios, adjusting for potential confounders. RESULTS: We identified 1470 and 1666 incident SLE cases in the early and late cohorts, respectively. In both cohorts, SLE patients had similar levels of excess mortality compared with their matched comparators [15.9 vs 7.9 deaths/1000 person-years (PY) in the early cohort and 13.8 vs 7.0 deaths/1000 PY in the late cohort]. The corresponding mortality hazard ratios were 2.15 (95% CI 1.63, 2.83) and 2.12 (95% CI 1.61, 2.80) in the early and late cohorts, respectively (P-value for interaction = 0.95). The absolute mortality differences were 8.0 (95% CI 4.3, 11.8) and 6.8 (95% CI 3.5, 10.0) deaths/1000 PY, respectively (P-value for interaction = 0.61). CONCLUSION: This general population-based cohort study suggests that excess mortality has not improved among SLE patients in recent years, remaining greater than double that of comparators, unlike RA during the same period. This highlights a critical unmet need for the development of new therapeutic agents and improved management strategies for SLE and its comorbidities.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Jorge AM, Lu N, Zhang Y, et al. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). Rheumatology (Oxford). 2018. PMID: 29121273. doi:10.1093/rheumatology/kex412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。